Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours ยท Estimated delivery Aug 1 - Aug 6
Nauck MA, DAlessio DA, Tirzepatide (2022) A dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)
Furthermore, SAM is decarboxylated by AdoMet decarboxylase to form decarboxylated SAM (dcSAM)
The identified metabolic biomarkers not only provide insights into the metabolic consequences of GHD but also have potential clinical applications in humans
US$ 28.79
US$ 24.71
US$ 28.33
US$ 26.25
US$ 26.23
US$ 25.51
US$ 21.77
US$ 20.54
US$ 22.61
US$ 26.20
